These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 31462297)

  • 1. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
    Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R
    Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma.
    Ma Y; Qi Y; Zhou Z; Yan Y; Chang J; Zhu X; Han J; Wu H; Tao Y; Fan F
    Phytomedicine; 2024 Jan; 122():155171. PubMed ID: 37925891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
    Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
    Front Immunol; 2020; 11():1299. PubMed ID: 32719675
    [No Abstract]   [Full Text] [Related]  

  • 10. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
    Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
    J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LY341495, an mGluR2/3 Antagonist, Regulates the Immunosuppressive Function of Myeloid-Derived Suppressor Cells and Inhibits Melanoma Tumor Growth.
    Morikawa N; Tachibana M; Ago Y; Goda H; Sakurai F; Mizuguchi H
    Biol Pharm Bull; 2018; 41(12):1866-1869. PubMed ID: 30504687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic cancer.
    Xun J; Jiang X; Liu B; Hu Z; Liu J; Han Y; Gao R; Zhang H; Yang S; Yu X; Wang X; Yan C; Zhang Q
    Int Immunopharmacol; 2024 Sep; 139():112696. PubMed ID: 39018692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.
    Kato R; Haratani K; Hayashi H; Sakai K; Sakai H; Kawakami H; Tanaka K; Takeda M; Yonesaka K; Nishio K; Nakagawa K
    Br J Cancer; 2021 Mar; 124(5):914-924. PubMed ID: 33299131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy.
    Jiang K; Li J; Zhang J; Wang L; Zhang Q; Ge J; Guo Y; Wang B; Huang Y; Yang T; Hao D; Shan L
    Int Immunopharmacol; 2019 Oct; 75():105818. PubMed ID: 31437795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
    Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-derived GLI1 promotes remodeling of the immune tumor microenvironment in melanoma.
    Giammona A; De Vellis C; Crivaro E; Maresca L; Amoriello R; Ricci F; Anichini G; Pietrobono S; Pease DR; Fernandez-Zapico ME; Ballerini C; Stecca B
    J Exp Clin Cancer Res; 2024 Aug; 43(1):214. PubMed ID: 39090759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
    Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
    Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.